|
IPC 2025 to bolster Bengaluru’s global stand as hub for CRAMS and GCCs, fuelled by quality talent
|
|
Nandita Vijayasimha, Bengaluru
December 19 , 2025
|
|
|
Indian Pharmaceutical Congress (IPC) 2025 is set to further elevate Bengaluru’s position as a global leader in Contract Research and Manufacturing Services (CRAMS) and Global Capability Centres (GCCs).
As the city continues to attract top pharmaceutical firms, IPC 2025 will showcase how Bengaluru's advanced infrastructure, robust talent pool, and thriving innovation ecosystem are driving the growth of both CRAMS and GCC sectors. With a focus on quality, qualified talent and technologies, Bengaluru is positioned to lead in pharmaceutical outsourcing, research, and development, making it an indispensable hub for global pharmaceutical excellence, said Jatish N Sheth, president, Karnataka Drugs and Pharmaceutical Manufacturers, member of the Local Organising Committee and heading the IPC 2025 expo committee.
The 3-day event is set to take place from December 19-21, 2025 in Bengaluru, one of India's most vibrant and innovative cities, known for its strong presence in the pharmaceutical and life sciences sectors 2025. This year’s congress promises to be a landmark event, bringing together industry leaders, researchers, policymakers, and professionals from across the globe to discuss the latest trends, innovations, and challenges in the pharmaceutical landscape.
With Bengaluru's growing reputation as a hub for GCCs in the life sciences space, IPC 2025 will explore developments in drug manufacturing, biotechnology, and pharmaceutical regulations. Attendees will have the opportunity to engage in insightful discussions, share knowledge, and foster collaborations that can drive the future of healthcare and pharmaceutical innovation, he added.
In addition to exploring breakthroughs in drug development, IPC 2025 will also highlight the growing role of contract manufacturing in the pharmaceutical industry. With Bengaluru's well-established infrastructure and advanced capabilities, the city is increasingly becoming a key player in contract manufacturing, offering state-of-the-art facilities and cutting-edge technology for both domestic and international pharmaceutical companies, said Sheth.
The congress will feature discussions on how contract manufacturing is driving cost-efficiency, accelerating time-to-market, and ensuring high-quality standards in drug production. Experts will shed light on the evolving regulatory landscape, the importance of strategic partnerships, and how contract manufacturing can contribute to the global supply chain in the post-pandemic world, noted Sheth adding that this will be an excellent platform for networking with leaders in contract manufacturing and discovering opportunities to enhance collaboration and innovation in the pharmaceutical sector.
The rapidly growing CRAMS sector, which has become a critical component in the global pharmaceutical supply chain. Bengaluru, with its robust ecosystem, has emerged as a key hub for CRAMS, providing a conducive environment for the development of high-quality drugs at competitive costs. The city’s advanced infrastructure and skilled workforce make it a preferred destination for global pharmaceutical companies looking for reliable partners for outsourced research, development, and manufacturing. In fact, 10 of the top ten pharma brands are outsourced for production from leading global pharma to companies in Bengaluru, noted Sheth.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|